Oxford Biosensors will accelerate development of its point-of-care testing technology through a new deal with Pfizer
Oxford Biosensors announces an exclusive development agreement with Pfizer to accelerate development of point-of-care diagnostic tests.
Pfizer will provide Oxford Biosensors with additional funding to accelerate development of Oxford Biosensors's novel testing technology that enables multiple analyte detection from a single drop of blood.
Oxford Biosensor is developing the first test panel, a lipid profile, which measures total cholesterol, HDL/LDL and triglyceride levels.
Under the agreement, Pfizer will fund additional tests for the screening and monitoring of patients at risk of coronary heart disease (CHD).
"We are delighted to be working with Pfizer on this exciting project", said David Hawksworth, managing director of Oxford Biosensors.
"It further validates the tremendous near-term market potential we envision by accelerating the development of our point-of-care testing technology".
